Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

The peroxisome proliferator-activated receptor PPAR-γ is one of three PPAR nuclear
receptors that act as ligand-activated transcription factors. In immune cells, the skin, and …

Background Methotrexate (MTX) has been used to treat psoriasis for over half a century.
Even so, clinical data characterising its efficacy and safety are sparse. Objective In order to …

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors and
comprise three different isoforms namely PPARα, PPARγ, and PPARβ/δ with PPARβ/δ being …

In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the
cornerstone of systemic treatment of psoriasis. MTX has been used for many years …

Psoriasis is a chronic, systematic, inflammatory disease in which multiple metabolic and
immunologic disturbances lead to lipid abnormalities, impaired glucose tolerance, metabolic …

Inflammation is a crucial physiological response of our body to any kind of noxa be it an
infection or tissue injury. However, this physiological process can be detrimental if …

Psoriasis is a common chronic inflammatory skin disease that manifests as scaly
erythematous plaques as a consequence of keratinocyte hyperproliferation and …

Background Over 29 years of clinical application, the Dermatology Life Quality Index (DLQI)
has remained the most used patient-reported outcome (PRO) in dermatology due to its …

Background Methotrexate (MTX) is a systemic treatment for plaque-type psoriasis. At the
time of approval, no dose-ranging studies were performed. Nowadays, a uniform dosing …